121 related articles for article (PubMed ID: 16895484)
1. Heparin modulation of human plasma kallikrein on different substrates and inhibitors.
Gozzo AJ; Nunes VA; Cruz-Silva I; Carmona AK; Nader HB; Faljoni-Alario A; Sampaio MU; Araújo MS
Biol Chem; 2006 Aug; 387(8):1129-38. PubMed ID: 16895484
[TBL] [Abstract][Full Text] [Related]
2. Glycosaminoglycans affect the interaction of human plasma kallikrein with plasminogen, factor XII and inhibitors.
Gozzo AJ; Nunes VA; Nader HB; Dietrich CP; Carmona AK; Sampaio MU; Sampaio CA; Araújo MS
Braz J Med Biol Res; 2003 Aug; 36(8):1055-9. PubMed ID: 12886459
[TBL] [Abstract][Full Text] [Related]
3. Characterization of kininogenase activity of an acidic proteinase isolated from human kidney.
Gomes RA; Juliano L; Chagas JR; Hial V
Can J Physiol Pharmacol; 1997 Jun; 75(6):757-61. PubMed ID: 9276160
[TBL] [Abstract][Full Text] [Related]
4. S(1)' and S(2)' subsite specificities of human plasma kallikrein and tissue kallikrein 1 for the hydrolysis of peptides derived from the bradykinin domain of human kininogen.
Lima AR; Alves FM; Angelo PF; Andrade D; Blaber SI; Blaber M; Juliano L; Juliano MA
Biol Chem; 2008 Dec; 389(12):1487-94. PubMed ID: 18844446
[TBL] [Abstract][Full Text] [Related]
5. Serine protease specificity for peptide chromogenic substrates.
Mattler LE; Bang NU
Thromb Haemost; 1977 Dec; 38(4):776-92. PubMed ID: 146272
[TBL] [Abstract][Full Text] [Related]
6. Kinetic study of the effect of heparin on the amidase activity of trypsin, plasmin and urokinase.
Yomtova VM; Stambolieva NA; Blagoev BM
Thromb Haemost; 1983 Jun; 49(3):199-203. PubMed ID: 6224310
[TBL] [Abstract][Full Text] [Related]
7. Proton inventory studies of alpha-thrombin-catalyzed reactions of substrates with selected P and P' sites.
Enyedy EJ; Kovach IM
J Am Chem Soc; 2004 May; 126(19):6017-24. PubMed ID: 15137766
[TBL] [Abstract][Full Text] [Related]
8. Studies on proteases and alpha-macroglobulin activity in amphibian blood plasma.
Kumar RS
Indian J Exp Biol; 1997 Nov; 35(11):1198-202. PubMed ID: 9567750
[TBL] [Abstract][Full Text] [Related]
9. Synthetic peptides and fluorogenic substrates related to the reactive site sequence of Kunitz-type inhibitors isolated from Bauhinia: interaction with human plasma kallikrein.
Oliva ML; Santomauro-Vaz EM; Andrade SA; Juliano MA; Pott VJ; Sampaio MU; Sampaio CA
Biol Chem; 2001 Jan; 382(1):109-13. PubMed ID: 11258660
[TBL] [Abstract][Full Text] [Related]
10. Mapping of human plasma kallikrein active site by design of peptides based on modifications of a Kazal-type inhibitor reactive site.
Nunes VA; Gozzo AJ; Sampaio MU; Juliano MA; Sampaio CA; Araujo MS
J Protein Chem; 2003 Aug; 22(6):533-41. PubMed ID: 14703987
[TBL] [Abstract][Full Text] [Related]
11. Glycosaminoglycans affect the action of human plasma kallikrein on kininogen hydrolysis and inflammation.
Gozzo AJ; Nunes VA; Carmona AK; Nader HB; von Dietrich CP; Silveira VL; Shimamoto K; Ura N; Sampaio MU; Sampaio CA; Araújo MS
Int Immunopharmacol; 2002 Dec; 2(13-14):1861-5. PubMed ID: 12489800
[TBL] [Abstract][Full Text] [Related]
12. High molecular weight kininogen potentiates the heparin-accelerated inhibition of plasma kallikrein by antithrombin: role for antithrombin in the regulation of kallikrein.
Olson ST; Sheffer R; Francis AM
Biochemistry; 1993 Nov; 32(45):12136-47. PubMed ID: 7692967
[TBL] [Abstract][Full Text] [Related]
13. Dextran sulphate inhibits phospholipid and sulphatide mediated autoactivation of factor XII.
Schousboe I; Rasmussen MS; Lintner R
Blood Coagul Fibrinolysis; 1994 Aug; 5(4):503-9. PubMed ID: 7841305
[TBL] [Abstract][Full Text] [Related]
14. A novel chromogenic peptide for prekallikrein/kallikrein determination.
Huang WY; Wan X; Zhang S
Clin Lab; 2009; 55(3-4):106-13. PubMed ID: 19462932
[TBL] [Abstract][Full Text] [Related]
15. Differences in substrate and inhibitor sequence specificity of human, mouse and rat tissue kallikreins.
Fogaça SE; Melo RL; Pimenta DC; Hosoi K; Juliano L; Juliano MA
Biochem J; 2004 Jun; 380(Pt 3):775-81. PubMed ID: 15040788
[TBL] [Abstract][Full Text] [Related]
16. Recombinant alpha 1-antitrypsin Pittsburgh (Met 358----Arg) is a potent inhibitor of plasma kallikrein and activated factor XII fragment.
Schapira M; Ramus MA; Jallat S; Carvallo D; Courtney M
J Clin Invest; 1986 Feb; 77(2):635-7. PubMed ID: 3484756
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of human pancreatic proteinases by human plasma alpha2-antiplasmin and antithrombin.
Nobar SM; Guy-Crotte O; Rabaud M; Bieth JG
Biol Chem; 2004 May; 385(5):423-7. PubMed ID: 15196003
[TBL] [Abstract][Full Text] [Related]
18. Fibrinolytic compromise by simultaneous administration of site-directed inhibitors of thrombin.
Callas D; Bacher P; Iqbal O; Hoppensteadt D; Fareed J
Thromb Res; 1994 May; 74(3):193-205. PubMed ID: 8042188
[TBL] [Abstract][Full Text] [Related]
19. Protection by recombinant alpha 1-antitrypsin Ala357 Arg358 against arterial hypotension induced by factor XII fragment.
Schapira M; Ramus MA; Waeber B; Brunner HR; Jallat S; Carvallo D; Roitsch C; Courtney M
J Clin Invest; 1987 Aug; 80(2):582-5. PubMed ID: 3497179
[TBL] [Abstract][Full Text] [Related]
20. Human plasma kallikrein and tissue kallikrein binding to a substrate based on the reactive site of a factor Xa inhibitor isolated from Bauhinia ungulata seeds.
Oliva ML; Andrade SA; Batista IF; Sampaio MU; Juliano M; Fritz H; Auerswald EA; Sampaio CA
Immunopharmacology; 1999 Dec; 45(1-3):145-9. PubMed ID: 10615004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
